The need to stratify the treatment of colorectal cancer with chemotherapy, based on whether or not KRAS mutations are present, exemplifies this,” concludes Roland Wolf, the study's principal ...

Explore the challenges and advancements in anti-EGFR antibody treatment for metastatic colorectal cancer. Discover how ...

Application to the European Medicines Agency (EMA) covers ANOC-001 as the initial product in the company’s VIDAR-1 Phase I/II multi-asset ...

DELHI, DELHI, INDIA, November 28, 2024 /EINPresswire / -- The Growth of the KRAS Inhibitors Market is expected to be mainly driven by increasing incidence, a rise in awareness and access to treatment, ...

KRAS G12C is the most common form of KRAS mutation in lung cancer, while G12D is found more commonly in other diseases like pancreatic and colorectal cancers. Dr Hu Tao, co-founder and chief ...

Amgen’s AMG 510 – which directly targets the G12C mutation – is currently ... less well in a second trial in colorectal cancer. Other players in the KRAS arena include Boehringer Ingelheim ...

colorectal, lung and small bowel tumours. In non-small cell lung cancer (NSCLC), the leading cause of cancer-related death, KRAS mutations are found in 25-30% of all cases with non-squamous histology.

Each year, more than 3 million people are diagnosed with cancers driven by mutations in three RAS-family genes: KRAS, NRAS ... of patients with lung cancer or colorectal cancer.